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Abstract 
Genome-wide association studies (GWAS) are highly effective at identifying 
common risk variants for schizophrenia. Rare risk variants are also important 
contributors to schizophrenia aetiology but, with the exception of large copy number 
variants (CNVs), are difficult to detect with GWAS. Exome and genome sequencing, 
which have accelerated the study of rare variants, are expensive so alternative 
methods are needed to aid detection of rare variants. Here we re-analyse an Irish 
schizophrenia GWAS dataset (n=3,473) by performing identity-by-descent (IBD) 
mapping followed by exome sequencing of individuals identified as sharing risk 
haplotypes to search for rare risk variants in coding regions. We identified 45 rare 
haplotypes (>1cM) that were significantly more common in cases than controls. By 
exome sequencing 105 haplotype carriers, we investigated these haplotypes for 
functional coding variants that could be tested for association in independent GWAS 
samples. We identified one rare missense variant in PCNT but did not find statistical 
support for an association with schizophrenia in a replication analysis. However, IBD 
mapping can prioritize both individual samples and genomic regions for follow-up 
analysis but genome rather than exome sequencing may be more effective at detecting 
risk variants on rare haplotypes. 
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Introduction 
Schizophrenia [MIM 181500] is a heritable mental disorder with a lifetime risk of 
~1%.  The emerging genetic architecture points to a spectrum of risk variation from 
common variants, likely to have subtle effects on gene expression, to functionally 
deleterious variants. Analysis of common risk variants has identified 108 independent 
schizophrenia associated risk loci (median odds ratio (OR) = 1.08) (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014), which collectively 
explain a small fraction of genetic risk (Loh et al., 2015). Analysis of rare copy 
number variants (CNVs) has identified a global enrichment of CNV burden in 
schizophrenia patients and eight individual risk loci reaching genome-wide 
significance (4 < OR < 68) (Marshall et al., 2017). The risk CNVs are rare, even in 
schizophrenia cases, and were identified by large case-control studies or meta-
analyses of array-based data (reviewed in Marshall et al., 2017). Such rare variants, 
having greater penetrance and a potentially clearer relationship to disease risk, may be 
most informative for functional follow-up studies (Karayiorgou, Flint, Gogos, 
Malenka, & Genetic and Neural Complexity in Psychiatry Working, 2012).  
 
Next-generation sequencing (NGS) has allowed the search for rare risk variants to 
extend to the exome and genome using both case-control and family-based designs. 
To date, genome sequencing has been limited to exploratory studies of multiplex 
families (Homann et al., 2016). A number of reasonably large case-control exome 
sequencing studies have now been reported and have identified gene-disruptive and 
putatively protein-damaging ultra-rare variants to be more abundant in cases than 
controls (Genovese et al., 2016). Initially, some small gene sets were thought highly 
enriched for rare disruptive variants (S. M. Purcell et al., 2014) but subsequent 
analyses suggest the enrichment is within a broader set of potentially synaptic genes. 
Results from the largest study to date, an analysis of 4,877 cases and 6,203 controls 
did not succeed in implicating any individual gene or risk variant after correction for 
multiple testing (Genovese et al., 2016). 
 
The association of schizophrenia with decreased fecundity has prompted the study of 
trios samples to detect de novo variants. Data from CNV studies support de novo 
variation as a contributing factor to the genetic aetiology of schizophrenia (Rees, 
Moskvina, Owen, O'Donovan, & Kirov, 2011). This has been confirmed by exome 
sequencing in trios implicating genes involved in synaptic function and chromatin 
remodelling, but also suggesting shared pathophysiology with other 
neurodevelopmental disorders such as autism and intellectual disability (Fromer et al., 
2014; McCarthy et al., 2014). But like the case-control studies, the trios studies did 
not specifically identify a new risk gene after multiple test correction. It took the 
novel combined analysis of case-control and trios exome data to identify SETD1A, a 
gene involved in chromatin remodelling, as a site of rare loss-of-function (LoF) 
variants increasing risk of schizophrenia after genome-wide correction (Singh et al., 
2016).  
 
With limited numbers of trios available for analysis and case-control sequencing 
studies remaining very expensive, the study of identity-by-descent (IBD) segments in 
genome-wide association study (GWAS) data is an alternative method for finding rare 
risk variants for schizophrenia. IBD segments represent chromosomal regions that are 
inherited without recombination from a common ancestor, and a signature of their 
presence is strong linkage disequilibrium across the segment that can be detected in 
GWAS data (Hou et al., 2013). IBD methods have been successfully applied in 
founder populations to identify genes for both monogenic (Brooks et al., 2009) and 
complex disorders (Morrow et al., 2008). In outbred populations, IBD methods have 
been successfully applied to map genes for neurodevelopmental disorders using array-
based SNP data with follow-up Sanger sequencing (Ercan-Sencicek et al., 2010) and 
using exome sequencing data (Krawitz et al., 2010) but these studies used family-
based samples. IBD methods have been applied to population-based GWAS data for 
multiple sclerosis but with limited success (Lin et al., 2013; Westerlind et al., 2015). 
 
Here, we detail a novel approach to rare risk variant detection in schizophrenia that 
combines IBD analysis of GWAS data and exome sequencing. We used IBD analysis 
of GWAS data from a homogeneous sample of Irish schizophrenia patients and 
controls (Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case 
Control Consortium 2, 2012) to search for shared haplotype segments in distantly 
related individuals and tested for haplotype segments that were more frequent in cases 
than controls. This approach identified a subset of key individuals to be sequenced 
and reduced the search space for mid to high effect rare variants that may have arisen 
de novo in more recent generations but have not been removed from the population by 
purifying selection (Lupski, Belmont, Boerwinkle, & Gibbs, 2011). After exome 
sequencing haplotype carriers, we investigated these segments to identify rare and 
potentially functional coding variants and then tested these variants for association in 
both our Irish and large international case-control samples.  
 
Materials and Methods 
Discovery Sample 
The discovery sample included cases and controls from the Irish Schizophrenia 
Genomics Consortium/WTCCC2 GWAS study, which has previously been described 
(Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control 
Consortium 2, 2012). Cases were recruited through community mental health services 
and inpatient units in the Republic of Ireland and Northern Ireland following similar 
research protocols and with local ethics approval. All participants were interviewed 
using a structured clinical interview (Structured Clinical Interview for DSM-III-R, 
Structured Clinical Interview for DSM-IV (First, Spitzer, Robert, Gibbon, & 
Williams, 2002); Schedule for Affective Disorders and Schizophrenia [Lifetime 
Version] (Endicott & Spitzer, 1978); or Schedule for Clinical Assessment in 
Neuropsychiatry (World Health Organization, 1992)). Diagnosis of a major psychotic 
disorder was made by the consensus lifetime best estimate method using DSM-III-R 
or DSM-IV criteria with all available information (interview, family or staff report, 
and chart review). All cases were over 18 years of age, were of Irish origin (being of 
Irish parents and having all four grandparents born in Ireland or the United Kingdom), 
and had been screened to exclude substance-induced psychotic disorder or psychosis 
due to a general medical condition. The final analysis included samples from 1,635 
participants whose SNP data passed quality control filters, described below, and met 
DSM-IV criteria for schizophrenia (or a related disorder).  
 
Control individuals were ascertained with written informed consent from the Trinity 
Biobank and represented blood donors from the Irish Blood Transfusion Service 
recruited in the Republic of Ireland. They met the same ethnicity criteria as cases but 
were not specifically screened for psychiatric illness. Individuals taking regularly 
prescribed medication are excluded from blood donation in Ireland and donors are not 
financially remunerated. As the lifetime prevalence of schizophrenia is relatively low 
(<1%) and there was no obvious reason for individuals with schizophrenia to be 
overrepresented in the control subjects, the fraction of putative case individuals in the 
control collection was expected to be small. Following QC, the control sample 
included 1,838 participants. 
 
Replication Samples 
GWAS data from 41 schizophrenia studies was accessed through the Psychiatric 
Genomics Consortium (PGC2 data) and a description of the individual datasets 
(which are based on individuals from Europe, North America, Australia and Asia, and 
genotyped on a variety of arrays) can be found in the 2014 PGC2 publication 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). 
Where possible, variants of interest were imputed in these datasets (maximum 
possible sample: 28,918 cases and 35,910 controls).  A further independent 
replication dataset from the UK comprised 5,585 cases from two collections, Cardiff 
COGS and CLOZUK, and 8,103 controls from the UK Blood Service donors and the 
1958 British Birth Cohort. Samples were genotyped using the Illumina HumanExome 
and HumanOmniExpressExome BeadChip arrays, as described by Richards et al. 
(Richards et al., 2016) 
 
Discovery GWAS: Genotype Calling 
All samples were genotyped using the Affymetrix 6.0 platform totalling 893,634 
autosomal SNPs, either at the Affymetrix (Santa Clara, California) or Broad Institute 
(Cambridge, Massachusetts) laboratories. For all samples passing laboratory quality 
control, raw intensities (from the .CEL files) were renormalized within collections 
using CelQuantileNorm (http://outmodedbonsai.sourceforge.net/). These normalized 
intensities were used to call genotypes with an updated version of the Chiamo 
software (https://mathgen.stats.ox.ac.uk/genetics_software/chiamo/chiamo.html), 
adapted for Affymetrix 6.0 SNP data. 
 
Discovery GWAS: Quality Control 
The primary GWAS has previously been reported and details of the original quality 
control methods were described therein (Irish Schizophrenia Genomics Consortium 
and the Wellcome Trust Case Control Consortium 2, 2012). For this analysis, SNP 
data was subjected to additional quality filters (variants with minor allele frequency 
<0.001, SNP missingness ≥0.02, Hardy-Weinberg equilibrium p≤10-6 were removed). 
SNP positions were updated to hg19. As the aim of this study was to identify shared 
regions of IBD between distantly related individuals, the previous stringent control on 
cryptic relatedness was relaxed such that the proportion of genome sharing between 
any possible pair of individuals was <0.1 (i.e. more distantly related than first 
cousins), rather than <0.05 as in the original study. In order to ensure a homogeneous 
sample, 4 individuals were removed that were identified as outliers in a multi-
dimensional scaling (MDS) analysis of pairwise genome-wide IBS distances 
(performed in PLINK (S. Purcell et al., 2007)).  
 
Discovery GWAS: Identification of IBD segments 
IBD segments shared between pairs of individuals were detected using the Refined 
IBD algorithm (B. L. Browning & Browning, 2013) within BEAGLE 4.0 (r1230) (S. 
R. Browning & Browning, 2007). Candidate segments were required to have a 
minimum length of 1cM and the likelihood ratio of an IBD model (one haplotype 
shared IBD) compared to a non-IBD model (no haplotypes shared IBD), i.e. the LOD 
score, was required to be >3. These are the default values as implemented in (B. L. 
Browning & Browning, 2013). 
 
Discovery GWAS: IBD mapping 
The efficient multiple-IBD (EMI) algorithm (Qian, Browning, & Browning, 2014) 
was used to identify clusters of individuals sharing a haplotype IBD. EMI was run 
using a window size of 200kb and a cluster density of 0.5 (as in Qian, Browning, & 
Browning, 2014). IBD segments with LOD scores between 3 and 40 were weighted 
0.8, IBD segments with LOD scores greater than 40 were weighted as 1. This resulted 
in a set of haplotype cluster files for each chromosome, detailing the genomic 
coordinates of each identified IBD segment (haplotype), and the individuals sharing 
each haplotype. Cluster files were converted to plink format for association testing. 
The association analysis was performed in PLINK (S. Purcell et al., 2007) and 
compared individual haplotype frequencies in cases versus controls. Haplotypes 
occurring significantly more frequently in cases than controls at p≤0.01 were taken 
forward for further analysis. A second strategy employed locus-based tests as opposed 
to the single haplotype tests performed previously. Each of the genomic regions 
containing multiple different IBD segments was considered a single locus, and the 
individual haplotypes within them were tested en masse using SKAT-O (Lee et al., 
2012). Of the three significant loci detected at a family-wise error rate of 0.05, any 
individual haplotype within these loci more frequent in cases than controls at p≤0.05 
was taken forward for further analysis. For each of the 45 haplotype segments 
selected from the two strategies, and where DNA was available for at least two 
individuals sharing that haplotype, exome sequencing was performed on each 
individual. A total of 118 individuals were sequenced, representing 32 haplotype 
segments. 
 
Exome Capture and Sequencing 
Exome capture was performed using the Solution Phase Exome Capture method, 
which is an optimization of the NimbleGen SeqCap EZ Library protocol and the BioO 
Scientific NEXTflex™ (Illumina Compatible) Sequencing Kit. (See Technology 
Note: Targeted Sequencing with NimbleGen SeqCap EZ Libraries and Illumina 
TruSeq DNA Sample Preparation kit). Briefly, sonicated genomic DNA ranging from 
1–5μg was used to create Illumina Barcoded libraries. Approximately 1μg of the pre-
capture library was hybridized with the NimbleGen SeqCap EZ Human Exome 
Library v3.0 probes  for 72 hours at 47°C. (For further details see the NimbleGen 
SeqCap EZ Exome User’s Guide and TechNote for paired-end libraries). Following 
dual capture, PCR enrichment and QC evaluation, samples with Bioanalyzer traces 
resulting in broad peaks ranging from 250bp–850bp and producing the highest peak 
around 400bp (DNA insert plus adaptors) were pooled (4-6 captures per pool). 
Libraries were sequenced on 1-2 lanes on a HiSeq 2000 with a Paired End 101 run 
including a 9 base pair index read for the barcode detection.  
 
Data Processing and Variant Calling 
Sequence reads from the Illumina HiSeq 2000 runs were de-multiplexed using the 
Illumina Casava v1.8 pipeline, aligned to hg19 using the BWA aligner (Li & Durbin, 
2009), allowing 2 mismatches in the 30-base seed. Alignments were then paired, 
imported to binary (bam) format, sorted and indexed using SAMtools (Li et al., 2009). 
Picard was then used to fix any mate pair information altered by the sorting. Bamtools 
(Barnett, Garrison, Quinlan, Strömberg, & Marth, 2011) was used to filter alignments 
to retain only properly paired reads (reads aligned with appropriate insert size and 
orientation). PCR duplicates were removed using Picard. Bamtools was then used to 
select alignments with a minimum mapping quality score of 20. Target coverage for 
each NimbleGen exome capture was assessed using Picard’s HSmetrics utility, and 
both depth and breadth of coverage were reviewed for each sample. The Genome 
Analysis Toolkit (GATK v3.3) (DePristo et al., 2011) was used for local read 
realignment around indels, and for base quality score recalibration using corrections 
for base position within the Illumina read, for sequence context, and for platform-
reported quality. Variants were called using the GATK Haplotype Caller in joint 
calling mode, followed by Variant Quality Score Recalibration (VQSR).  Twelve 
samples were excluded due to low coverage. 
 
Variant Filtering and Phasing 
The VCF file was filtered to retain variants passing variant quality recalibration and to 
ensure ≥10X depth at the individual level (using vcftools (Danecek et al., 2011)) and 
quality by depth (QD) ≥5 at the variant level (using GATK (DePristo et al., 2011)). 
Samples were checked for concordance with GWAS data; all samples but one were 
>99% concordant for overlapping SNPs. The remaining discordant sample was 
determined to be a result of sample mix-up at the GWAS stage. Thus, sequence data 
was available for 105 individuals, representing 32 individual haplotype segments. As 
the analysis is focused on variants shared IBD by at least two individuals, all 
singleton and private doubleton variants were excluded. Allele counts were updated 
and non-polymorphic variants (post-filtering) removed. Variant IDs were updated to 
dbSNP142 rs# IDs where available (using SnpSift (Cingolani, Patel, et al., 2012)). 
Variants were annotated with SnpEff (Cingolani, Platts, et al., 2012) and the Variant 
Effect Predictor (VEP) (McLaren et al., 2010). The data was phased using Beagle 4.0 
(r1230) and the haplotypes shared IBD between individuals, detected through the IBD 
mapping step, were identified. 
 
Sanger Sequencing 
Carriers of the PCNT variant rs143796569 (NC_000021.8:g.47817316G>A) 
identified through the exome study were Sanger sequenced (primer sequences are 
available on request) and all individuals were confirmed as heterozygotes. Selected 
individuals that were predicted to be carriers following imputation (see below) were 
also verified by Sanger sequencing. 
 
Imputation 
The exome sequencing data was merged with existing GWAS data for the 105 
sequenced individuals and the resulting dataset was used to create a reference panel 
using SHAPEIT v2 (Delaneau, Marchini, & Zagury, 2012).  This Irish reference panel 
was merged with the 1000 Genomes Phase I integrated panel (Dec 2013 release; 
http://www.internationalgenome.org/) and used to impute identified variants of 
interest into (1) the full Irish GWAS dataset and (2) individual PGC2 GWAS datasets. 
Association of variants with schizophrenia was tested using a score test implemented 
in SNPTEST v2 (Wellcome Trust Case Control Consortium, 2007). 
 
Results 
Figure 1 is a flow chart that summarizes the analytical methods used in this study. 
Seeking to identify relatively recent variants impacting on schizophrenia risk in a 
homogenous population, we performed IBD mapping using data generated from a 
previously published GWAS of Irish schizophrenia patients and controls (Irish 
Schizophrenia Genomics Consortium and the Wellcome Trust Case Control 
Consortium 2, 2012). We identified segments of the genome (>1cM) predicted to be 
shared IBD between pairs of individuals using the Refined IBD algorithm within the 
Beagle software (B. L. Browning & Browning, 2013). We subsequently performed 
clustering of the identified segments using the efficient multiple-IBD (EMI) algorithm 
(Qian et al., 2014) to identify haplotype segments shared by at least three individuals. 
As a result, 11,442 haplotype segments (each shared IBD between at least 3 people) 
were identified.  
 
For each of the 11,442 segments, the proportion of haplotype carriers in the patient 
group was compared with the proportion of haplotype carriers in the control group.   
Following correction for multiple testing, no individual haplotype segment was 
significantly associated with schizophrenia. However, as this was considered an 
exploratory analysis, twenty-eight haplotype segments that were more frequent in 
cases than controls at uncorrected p≤0.01 (listed in Supplementary Table 1) were 
taken forward for further analysis. To capture the potential impact of multiple risk 
variants at a locus, multiple different IBD segments at a locus were collapsed and the 
individual haplotypes within them were tested en masse using SKAT-O (Lee et al., 
2012). Forty loci were tested and three were significant after controlling for a family-
wise error rate of 0.05 by resampling. Within these loci, 17 individual haplotype 
segments were observed more frequently in cases than controls at p≤0.05 (listed in 
Supplementary Table 1) and were taken forward for further analysis. In total, 45 
haplotype segments were selected for further analysis. 
 
Hypothesising that rare haplotypes more frequently observed in cases than controls 
may harbour susceptibility variants of moderate to large effect, we focused on the 
coding sequence of the prioritised segments. Where DNA was available, we 
performed exome sequencing in carriers of the prioritised haplotypes (118 
individuals). One hundred and five individuals passed quality control, allowing us to 
analyse 32 of the selected 45 haplotype segments (each with at least 2 carriers 
successfully sequenced).  
 
Of the identified sequence variants, those lying within haplotype segment regions 
were extracted and annotated with SnpEff and VEP. Initially high impact variants 
(e.g. frameshift, nonsense, splice site variants) that were either novel or with a minor 
allele frequency ≤0.01 in public databases (1000 Genomes European population, the 
NHLBI GO Exome Sequencing Project (ESP; https://esp.gs.washington.edu/drupal/) 
European Ancestry population, the Exome Aggregation Consortium (ExAC; 
http://exac.broadinstitute.org/) European population) were assessed. However, of the 
30 variants identified, none were carried by all sequenced members of a haplotype 
cluster. We then assessed moderate impact variants (e.g. missense variants, inframe 
indels) that were either novel or with a minor allele frequency ≤0.01 in public 
databases. Of the 159 moderate impact variants identified, three variants were carried 
by all sequenced members of a relevant haplotype cluster (Table 1). One of these 
variants was also carried by additional sequenced cases not identified in the original 
IBD analysis (see Table 1). Each variant was examined to determine if it was carried 
on the shared IBD haplotype identified in the original analysis. This was only the case 
for one of the variants; a rare, non-synonymous variant in the PCNT gene, 
rs143796569 (chr21:47817316 G>A; hg19; NP_006022.3:p.Gly1452Arg), that was 
confirmed by Sanger sequencing. The variant causes a glycine to arginine change in 
the protein and is predicted to be “probably damaging” by PolyPhen (Adzhubei et al., 
2010) but “tolerated” by SIFT (Kumar, Henikoff, & Ng, 2009). Of the 11 cases and 1 
control that were identified as sharing a haplotype at this locus, DNA was available 
for 5 individuals (all cases), which were sequenced; all 5 carried the alternate allele of 
the PCNT variant on the shared haplotype. The variant had been previously identified 
in other studies, with a minor allele frequency of 0.0025 in 33,330 non-Finnish 
Europeans (ExAC), but was not observed in the 1000 Genomes data. 
 
We used the exome and GWAS data of the 105 sequenced individuals, in conjunction 
with 1000 Genomes data, to generate a merged reference panel in order to impute 
unobserved genotypes at the PCNT locus. The rs143796569 variant was successfully 
imputed in the original Irish GWAS data and predicted to be carried by all individuals 
sharing the haplotype segment; however, it was also predicted to be carried by several 
additional cases and controls. When tested for association with schizophrenia in the 
full GWAS sample, the minor allele of the imputed variant was present at a higher 
frequency in cases compared with controls, although this was not statistically 
significant (p=0.057, odds ratio=1.77, 95% confidence interval (C.I.)= 0.98-3.17).  
 
The haplotype segment originally identified comprised 205 GWAS SNPs, covering 
almost 1 Mb on chromosome 21 (chr21:47,013,876-47,964,259; hg19). We 
investigated the haplotypes of the additional carriers of the rs143796569 rare allele 
identified through imputation and determined that these individuals all share a shorter, 
~500kb haplotype that is identical to the 3’ end of the 1Mb haplotype 
(chr21:47,503,311-47,964,259; hg19). Thus, while the rs143796569 rare allele is 
carried on the 1Mb rare haplotype, it is not exclusive to it.  
 
We nevertheless sought to examine the rs143796569 variant in independent datasets. 
Using the 1000 Genomes/Irish merged reference panel, we attempted to impute the 
variant in 41 GWAS datasets from the PGC2 schizophrenia study; the variant was 
successfully imputed (info>0.5) and analysed in 7 datasets (see Table 2), comprising 
6,889 cases and 8,043 controls. Random effects meta-analysis of all 7 datasets was 
not significant (p=0.58, odds ratio=1.32, 95% C.I.= 0.49-3.59). We also assessed an 
independent dataset from the UK, in which the variant had been directly genotyped. 
Again, there was no evidence for association with schizophrenia (p=0.32). 
 
Discussion 
We performed IBD mapping in an Irish schizophrenia GWAS dataset and selected 45 
genomic regions where a rare haplotype, >1cM in length, was more frequent in cases 
compared to controls. For 32 of these regions, we were able to perform exome 
sequencing on at least two individuals that shared a rare haplotype. Using functional 
annotation tools and data on allele frequencies from a number of large-scale exome 
and genome sequencing projects, we examined these shared haplotypes for rare 
protein-altering variants that could increase risk of schizophrenia. We succeeded in 
identifying a single missense variant in PCNT that was present on a rare haplotype 
and more frequent in sequenced cases compared to controls. Using 1000 Genomes 
and our Irish exome sequencing data as a merged reference panel, we were able to 
impute this variant into our full Irish GWAS dataset; although the rare allele was 
more frequent in cases than controls, the test for association was not statistically 
significant (p=0.057). Subsequent efforts in larger independent replication samples 
did not provide further support for association between this variant and schizophrenia. 
 
We consider two possible explanations for our findings in this region: 1. Our 
detection of the rare 1Mb haplotype in 11 cases versus 1 control in our GWAS sample 
was a chance result and does not reflect a rare risk variant at this locus. This spurious 
association led us to the PCNT variant, which is not associated with schizophrenia. 2. 
This 1Mb haplotype does carry a rare risk variant but it is not the PCNT variant and 
we could not find it using our approach here. When we imputed the PCNT variant 
into our GWAS sample, we found that it is not exclusively present on the 1Mb 
haplotype. As such, if there is a rare risk variant on the 1Mb haplotype that is 
responsible for the initial association signal after IBD analysis, it is not in complete 
linkage disequilibrium with the PCNT variant. Frustratingly, we could not find any 
variant, regardless of functional impact on coding sequence, in our exome data that 
was exclusive to and would effectively tag the 1Mb haplotype. Thus, we could test 
the PCNT variant in replication samples, but in the absence of a tagging variant we 
were not able to specifically test the 1Mb haplotype itself for independent evidence of 
association with schizophrenia.  
 
While we have shown that this approach can identify rare risk haplotypes in GWAS 
data, the challenge in subsequent analysis of these haplotypes is that they are large, 
making the task of tagging them and pinpointing potential risk variants difficult. For 
the vast majority of the IBD haplotypes we found to be more frequent in cases 
compared to controls, we did not find a suitable variant to bring forward for 
association analysis. We concentrated on variants that we detected in coding 
sequences of genes via exome sequencing. The advantages to this approach were that 
we were better able to assess the functional impact of variants on protein coding 
genes and we could use large datasets from exome sequencing projects to measure the 
frequency of coding variants detected in European populations. It is possible that we 
missed functional variants in these haplotypes because they exist outside of coding 
regions or because they are difficult to detect using exome sequencing, e.g CNVs 
(Tan et al., 2014). Full analysis of the haplotypes using complete genome data would 
better capture all variants. Interpretation of these data will remain challenging until 
knowledge to support functional annotation of non-coding regions increases. 
Importantly, genome sequencing would provide a better opportunity to at least 
identify variants that exclusively tag rare risk haplotypes and can be used in 
replication association studies, even if the task of finding actual causal variants 
persists. 
 
As with any approach using GWAS data, larger sample sizes will provide more power 
to detect associations. An accurate IBD method for rare variant analysis of GWAS 
data is very appealing, as there are vast quantities of GWAS data available for re-
analysis. The challenge is that these data were generated on numerous cohorts drawn 
from many diverse populations. IBD mapping is more effective in relatively 
homogeneous samples such as the Irish data used here. Increasing sample size means 
analysis of more heterogeneous samples, which can cause false-positive IBD mapping 
signals (S. R. Browning & Thompson, 2012). 
 The availability of whole genome sequence data for a case-control sample would 
make IBD mapping irrelevant because the utility of identifying IBD segments is in 
their capacity to infer untyped variants, which would be present in sequence data (S. 
R. Browning & Thompson, 2012). At present however, the cost of genome 
sequencing has not dropped sufficiently to make this feasible. In the meantime, the 
application of IBD mapping to GWAS data warrants investigation. Our study was 
able to find large rare haplotypes that were significantly more frequent in cases 
compared to controls but full sequencing of the prioritised genomic segments rather 
than exome sequencing may have been more effective for mapping or tagging risk 
variants for replication analysis. 
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Titles and legends to figures 
 
Figure 1: Flow chart highlighting the methods used in our IBD analysis of an Irish 
GWAS dataset. This study identified rs143796569 in PCNT as a putative rare risk 
variant for schizophrenia but subsequent analyses in independent case-control 
samples did not support association with schizophrenia. 
 
